# EDGAR Filing Document

**Accession Number:** 0001048477
**File Stem:** 0001193125-23-006489
**Filing Date:** 2023-1
**Character Count:** 12270
**Document Hash:** 75e5790834a8f5f8d083d0370ead54cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-006489.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001193125-23-006489

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOMARIN PHARMACEUTICAL INC
- **CENTRAL INDEX KEY:** 0001048477
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 680397820
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-26727
- **FILM NUMBER:** 23523801

**BUSINESS ADDRESS:**
- **STREET 1:** 105 DIGITAL DRIVE
- **CITY:** NOVATO
- **STATE:** CA
- **ZIP:** 94949
- **BUSINESS PHONE:** 4155066700

**MAIL ADDRESS:**
- **STREET 1:** 105 DIGITAL DRIVE
- **CITY:** NOVATO
- **STATE:** CA
- **ZIP:** 94949

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 9, 2023

------

## BioMarin Pharmaceutical Inc.

#### (Exact name of Registrant as Specified in Its Charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-26727** | **68-0397820** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission<br>File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **770 Lindaro Street, San Rafael, California** | **94901** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (415) 506-6700

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.001 | BMRN | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On January 9, 2023, BioMarin Pharmaceutical Inc. (the "Company") presented a business update at the 41st Annual J.P. Morgan Healthcare Conference (the "Presentation"), during which the Company disclosed that based on preliminary results the Company estimates that it generated approximately $2.09 billion in total revenues (unaudited) for the year ended December 31, 2022, including approximately $169 million in revenues (unaudited) for the year ended December 31, 2022 from sales of VOXZOGO<sup>®</sup>. The information in this Item 2.02 is unaudited, preliminary, and subject to the Company's normal quarterly and annual accounting and financial statement closing procedures. The information in this Item 2.02 does not present all information necessary for an understanding of the Company's results of operations for the fiscal year ended December 31, 2022, and should not be viewed as a substitute for full financial statements prepared in accordance with U.S. generally accepted accounting principles. There can be no assurance that actual results will not differ from the preliminary estimates in this Item 2.02. The Company expects to report its results for the fourth quarter and full year 2022 in February 2023. The Presentation was previously announced by press release and was made available to the public via simultaneous webcast, and the slides that accompanied the Presentation were made available to the public on the Company's website. A copy of the relevant slides relating to the aforementioned financial updates is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 99.1 | [Relevant Slides from BioMarin Pharmaceutical Inc. J.P. Morgan 2023 Presentation, dated January 9, 2023.](d405652dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### Forward Looking Statements
*This current report on Form 8-K contains forward-looking statements about the financial performance of BioMarin Pharmaceutical Inc., including preliminary estimated unaudited total revenues for the year ended December 31, 2022, including revenues from sales of VOXZOGO <sup>®</sup>. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: completion of BioMarin's normal quarterly and annual accounting and financial statement closing procedures for the quarter and the year ended December 31, 2022, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.* 

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | BioMarin Pharmaceutical Inc.,<br> a Delaware corporation | BioMarin Pharmaceutical Inc.,<br> a Delaware corporation |
| Date: January 11, 2023 | By: | /s/ G. Eric Davis |
|  |  | G. Eric Davis<br> Executive Vice President, Chief Legal Officer |

---

## Exhibit 99.1

![](g405652ex99_1p1g1.jpg)

Exhibit 99.1 • 41st Annual J.P. Morgan ai0MARIN Healthcare Conference January 9, 2023 Transforming Lives Through Genetic Discovery J.J. Bienaime Chairman and Chief Executive Officer

------

![](g405652ex99_1p2g1.jpg)

Safe Harbor This non -confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the expected financial performance of BioMarin, including, without limitation, preliminary unaudited total revenues and revenue from sales of VOXZOGO for fiscal year 2022, double-digit revenue growth in 2023, sustainable growth and profitability, profit margin expansion, mid-decade revenues, and other specified financial guidance; the markets for BioMarin's products and product candidates, including, without limitation, the addressable patient populations in BioMarin territories and commercial market opportunities; and BioMarin's development of product candidates and commercialization of products, including, without limitation, IND submissions anticipated in 2023, the outcome of BioMarin's BLA resubmission for ROCTAVIAN to the FDA, and the commercial launch of ROCTAVIAN. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: completion of BioMarin's normal quarter and year-end accounting procedures for the quarter and the year ended December 31, 2022 and completion of the external audit with respect to such periods by BioMarin's independent registered public accounting firm; results and timing of current and planned preclinical studies and clinical trials; BioMarin's ability to successfully manufacture its commercial products and product candidates; the content and timing of decisions by the FDA, the European Commission and other regulatory authorities concerning products and product candidates; BioMarin's success in the commercialization of its commercial products; and those factors detailed in the press release issued January 8, 2023, as well as BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption Risk Factors in BioMarin's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward -looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward - looking statement, whether as a result of new information, future events or otherwise. BiOMARI N 2

------

![](g405652ex99_1p3g1.jpg)

Significant Future Growth Expected Driven by VOXZOGO and ROCTAVIAN VOXZOGO & ROCTAVIAN N $46 - $56 >2x New Base $4B-$5B Products Products -50% -50% Mid-Decade $2.09B $1.85B N 2021 20221 Mid- / End of Decade Decade All other products Anticipated Revenue Growth Enablers Continued growth within Base indication launch of Regulatory approval of U.S. Expansion of VOXZOGO & base portfolio VOXZOGO & ROCTAVIAN ROCTAVIAN ROCTAVIAN indications BIOMARIN 6 1 Unaudited preliminary 2022 revenue estimate

------

![](g405652ex99_1p4g1.jpg)

(ACH) VOXZOGO: Opportunity to Expand Markets in Achondroplasia 1,000+ Additional Children Eligible for Treatment upon Anticipated U.S. and E. U. Age Expansions VOXZOGO Achondroplasia Market Opportunity Launch Excellence 2022 Commercial Execution $3B+ • 1 year anniversary Annual • Over 1,000 children treated at 800 18,000+ Market 300 Opportunity year-end -17,000 • 32 active markets to date Approved • $169M1 expected 2022 revenue age ranges: • U.S. 5+ 2023 Opportunities • Japan all • Continued uptake of patients, and • EMA 2+ expansion into additional new • ROW 2+ markets ACH U.S. Total Potential EMA Initially • Potential age label expansions in Indicated Expansion Indicated ACH Indicated Expansion Market Value Age <5 Patients Patients Age <2 the U.S. and Europe (Approximately 1,000 newborns with achondroplasia born each year in BioMarin territories) BiOIMARIN 9 1 Unaudited preliminary 2022 revenue estimate